Form 4: Merus CEO Sells Shares in Genmab Tender Offer

Merus N.V.'s President and CEO, Sven Ante Lundberg, disposed of all his common shares and cancelled all share options as part of Genmab's $97.00 per share tender offer.

Summary

• Sven Ante Lundberg, President, CEO & PEO of Merus N.V., disposed of all his beneficial ownership in Merus N.V. common shares and derivative securities.
• This occurred on December 12, 2025, as part of a tender offer by Genmab A/S (through its wholly owned subsidiary Genmab Holding II B.V.) for Merus N.V. common shares.
• The tender offer consideration was a cash payment of $97.00 per share, without interest and less applicable withholding taxes.
• Lundberg disposed of a total of 86,435 common shares, including 30,297 directly held and 56,138 indirectly held through various trusts.
• Multiple share options with exercise prices ranging from $13.52 to $41.65 were cancelled, with cash compensation equal to the difference between the $97.00 offer price and the option's exercise price.
• Following these transactions, Lundberg's beneficial ownership in Merus N.V. common shares and derivative securities is zero.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a tender offer at a premium price of $97.00 per share, allowing the CEO to monetize his holdings and options. This is a positive liquidity event for the reporting person and other shareholders who participated.

Positives

• Sven Ante Lundberg received $97.00 per share for all his common shares, totaling approximately $8,384,195 (86,435 shares * $97.00).
• Share options were cancelled for cash, providing liquidity based on the difference between the $97.00 offer price and the option's exercise price.
• The tender offer by Genmab A/S was successfully completed, indicating a positive outcome for shareholders who tendered their shares at the specified price.

Negatives

• The reporting person no longer holds any beneficial ownership in Merus N.V. common shares or derivative securities following the transaction, signifying the end of his equity stake in the independent entity.

Future Outlook

The filing details the completion of a tender offer by Genmab A/S for Merus N.V., resulting in the acquisition of Merus. No specific forward-looking statements or guidance for the combined entity are provided within this Form 4.

Industry Context

The acquisition of Merus N.V. by Genmab A/S reflects ongoing consolidation and strategic M&A activity within the biotechnology and pharmaceutical sectors, where larger players often acquire innovative smaller companies to expand pipelines or gain new technologies.

Related Party Transactions

• Sven Ante Lundberg disposed of shares held indirectly through various family trusts, including Ante S Lundberg Qualified Annuity Interest Trust XI, Ante S Lundberg Qualified Annuity Int Trust X, Katrina Lundberg 2018 Irrevocable Trust, Madeleine Lundberg 2018 Irrevocable Trust, Kristian Ante Lundberg 2018 Irrevocable Trust, and Emily Lundberg 2018 Irrevocable Trust. He and members of his immediate family are the sole beneficiaries of these trusts.

Stakeholder Impact

• Shareholders who tendered their shares received a cash payment of $97.00 per share, representing a significant liquidity event.
• The reporting person, Sven Ante Lundberg, as a key executive, has fully monetized his equity stake in Merus N.V. through this acquisition.
• The acquisition by Genmab A/S implies a change in ownership and control for Merus N.V., which will likely impact its future strategic direction and potentially its employees, though specific details are not in this filing.

Key Dates

Keywords

Merus N.V., MRUS, Genmab, Tender Offer, Acquisition, Form 4, Insider Transaction, Share Sale, Executive Compensation, Sven Ante Lundberg